Cedars-Sinai Cancer investigators have developed a new nanotechnology-based test that can detect and profile prostate cancers-;even in microscopic amounts.
Cedars-Sinai Cancer investigators have developed a new nanotechnology-based test that can detect and profile prostate cancers even in microscopic amounts.
Investigators from Cedars-Sinai Cancer have identified an investigational therapeutic approach that could be effective against treatment-resistant prostate cancer. Results of their Phase II clinical trial, published in the peer-reviewed journal Molecular Therapy, have led to a larger, multicenter trial that will soon be underway.